

CURRICULUM VITAE

Craig F. Ferris

PRESENT ADDRESS

Department of Psychology, Northeastern University, 360 Huntington Avenue
Boston, Massachusetts 02115-5000, E-mail: c.ferris@neu.edu

EDUCATION

1980 - 1981	Postdoctoral Training in Neuroendocrinology, Harvard Medical School, Boston, Massachusetts
1976 - 1979	Ph.D. – Physiology, New York Medical College, Valhalla, New York
1974 - 1976	M.S. - Physiology, New York Medical College, Valhalla, NY
1970 - 1974	B.S. - Biology, University of Massachusetts, Amherst, Massachusetts

APPOINTMENTS

2007-present	Professor of Psychology, Director, Center for Translational NeuroImaging, Northeastern University, Boston Massachusetts
1994- 2007	Professor of Psychiatry and Physiology, Director, Center for Comparative Neuroimaging, Department of Psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts.
1986 - 1993	Associate Professor, Department of Physiology, University of Massachusetts Medical School, Worcester, Massachusetts
1988 - 1998	Adjunct Professor, Department of Psychology, College of the Holy Cross, Worcester, Massachusetts
1987 - 1995	Adjunct Professor, Department of Biology, Clark University, Worcester, Massachusetts
1982 - 1986	Assistant Professor, Department of Physiology, University of Massachusetts Medical School, Worcester, Massachusetts
1980 - 1981	Research Fellow, Laboratory of Human Reproduction and Reproductive Biology, Harvard Medical School, Boston, Massachusetts
1978 - 1979	Instructor of Biology, Department of Biology, Westchester Community College, Valhalla, New York

HONORS AND AWARDS:

1979 - National Student Research Forum, Roche Laboratories Award in Neuroscience, First Place, for paper entitled "A Central Mechanism for the Feedback Control of Vasopressin."

1979- National Student Research Forum, Mead Johnson Excellence of Research Award, Second

Place, for paper entitled "A Central Mechanism for the Feedback Control of Vasopressin."

1980 - Postdoctoral Fellowship NIH Training Program in Endocrinology, Harvard Medical School, Boston, Massachusetts

1985 - Joseph P. Healey Award given by the University of Massachusetts Board of Trustees

1997 - Elected to the Academy of Behavioral Medicine Research

COMMERCIAL START-UPS

Co-founder and consultant AZEVAN PHARMACEUTICALS, Inc. (AZV), 115 Research Drive, Bethlehem, Pennsylvania. Founded in 1997, AZV's mission is to develop new drugs for treating impulsivity, aggression/violence, and self injurious behavior in the management of autism, Tourette's syndrome, mental retardation, and dementia of the Alzheimer's type.

Co-founder and CEO, INSIGHT NEUROIMAGING SYSTEMS, LLC, (INSL), 11 Canterbury Street, Worcester, Massachusetts. Founded in 1998, INSL provides custom-built radiofrequency coils and small animal restrainers for animal studies and clinical coils for breast imaging.

Co-founder and consultant, EKAM IMAGING, Inc. Founded in 2008, EKAM is a contract-research organization using MRI and SPECT/PET to expedite drug discovery for pharmaceutical and biotechnology companies.

PATENTS

Method and Apparatus for Performing Neuroimaging

issued – 8/14/2001 #6,275,723 USA

issued – 3/23/2004 #6,711,430 USA

issued – 3/29/2005 #6,873,156 USA

issued – 3/11/2008 #7,343,194 USA

Dual-tuned Microstrip Resonator Volume Coil

issued – 9/23/2008 #7,427,861 USA

Animal Holder for Neuroimaging

issued -12/15/2016 # 13,648,518 USA

US2019/0246938 Quantitative Magnetic Resonance Imaging of the Vasculature

US2020/12191 Quantitative Measurements of Disruption in the Blood Brain Barrier

US2020/015223 Quantitative Measurements of the Perivascular Space for CNS and Brain Disorders

COPY RIGHTS

Certified Registration # TXu 1-894-939 Brain Atlas: Vole

Certified Registration # TXu 1-962-649 Brain Atlas: Marmoset

Certified Registration # TXu 1-899-990 Brain Atlas: Mouse

MEMBERSHIPS

Society for Neuroscience, International Society for Research on Aggression, Academy of Behavioral Medicine Research, Society for Behavioral Neuroendocrinology, International Society for Magnetic Resonance in Medicine.

JOURNAL REVIEW

Brain Research, Brain Research Bulletin, Life Science, Physiology and Behavior, Critical Reviews in Neurobiology, American Journal of Physiology, Science, Neuroscience and Behavioral Reviews, Journal of Cellular Biochemistry, Journal of Neuroendocrinology, FESB, Hormones and Behavior, Biological Psychiatry, Journal of Neurobiology, Behavioral Neuroscience, Journal of Neuroscience

GRANT REVIEW

Harry Frank Guggenheim Foundation, National Science Foundation, National Institutes of Health, Whitehall Foundation, Phillip Morris

RESEARCH SUPPORT

Neurotensin and the Central Regulation of LH Release

National Institute of Child Health and Human Development – R01 HD18022

Principal Investigator: Craig F. Ferris, Project Period: 4/1/83 - 3/31/86, Total Costs: \$425,000

Alcohol Stimulated Release of Neurotensin

Scientific Advisory Council to Distilled Spirits Council of the United States

Principal Investigator: Craig F. Ferris, Project Period: 6/1/84 - 5/31/85, Total Costs: \$17,500

Substance P Regulation of Catecholamine Release from the Adrenal Medulla

Biomedical Research Support Grant

Principal Investigator: Craig F. Ferris, Project Period: 4/1/84 - 3/31/85, Total Cost: \$5,623

Ethanol Stimulated Release of Neurotensin from Human Small Intestine

Healy Endowment Grant

Principal Investigator: Craig F. Ferris, Project Period: 1/1/85 - 1/1/86, Total Cost: \$5,000

Vasopressin and Flank Marking Behavior

National Institute of Neurological and Communicative Disorders and Stroke – R01 NS23557

Principal Investigator: Craig F. Ferris, Project Period: 08/01/86-07/31/90, Total Costs: \$576,000

Role of Vasopressin in Ethanol-Mediated Aggression

Harry Frank Guggenheim Foundation

Principal Investigator: Craig F. Ferris, Project Period: 8/1/90 - 7/31/91, Total Costs: \$32,000

Neural Development of Communicative Behavior

National Science Foundation - BNS 9121097

Principal Investigator: Craig F. Ferris, Project Period: 1/1/92 - 12/31/94, Total Costs: \$323,000

Vasopressin/Oxytocin and the Control of ACTH Release

National Institute of Neurologic and Communicative Disorders – R01 NS30199

Principal Investigator: Craig F. Ferris, Project Period: 7/1/92 - 6/30/95, Total Costs: \$452,000

Vasopressin and Aggression: Testing Orally Active V1-Receptor Antagonists for Antiaggressive and Serenic Activities

Lilly Research Laboratories, Indianapolis, Indiana

Principal Investigator: Craig F. Ferris, Project Period: 05/01/92 - 12/31/95, Total Costs: \$68,000

Imaging Synaptic Connectivity with Wide-Field Digital Microscopy

National Science Foundation - IBN9419100

Principal Investigator: Craig F. Ferris, Project Period: 9/1/94 - 8/31/96, Total Costs: \$175,000

Neural Biology of Active Approach and Retreat

National Institute of Mental Health – R01 MH52280

Principal Investigator: Craig F. Ferris, Project Period: 1/1/96 - 12/31/99, Total Costs: \$861,000

Adolescent Stress and Neural Plasticity

National Institute of Mental Health – R01 MH52280-05

Principal Investigator: Craig F. Ferris, Period: 1/1/00 - 12/31/05, Total Costs: \$1,144,566

Noninvasive Devices for fMRI Studies in Mental Illness

National Institute of Mental Health - R42 MH59501

Principal Investigator: Craig F. Ferris, Project Period: 1/1/99 - 12/31/01, Total Costs: \$599,980

Imaging Brain Activity During Sexual Motivation

National Institute of Mental Health – R01 MH58700

Principal Investigator: Craig F. Ferris, Project Period 1/1/00 - 12/31/03, Total Costs: \$1,262,039

MRI of Brain Function and Receptors in Cocaine Addiction

National Institute on Drug Abuse - R01 DA133517

Principal Investigator: Craig F. Ferris, Project Period 8/1/01 – 7/31/06, Total Costs: \$1,609,560

Noninvasive Devices for fMRI Studies in Cocaine Abuse

National Institute on Drug Abuse – R41 DA013867 Phase I

Principal Investigator: Craig F. Ferris, Project Period: 1/1/01 – 12/31/02, Total Costs: \$100,000

Gradient Coil to Enhance MRI Research in Mental Illness

National Institute of Mental Health – R41 MH064970 Phase I

Principal Investigator: Craig Ferris, Project Period: 1/3/02 – 3/12/02, Total Cost \$100,000

Noninvasive Devices for fMRI Studies in Rhesus Monkeys

National Institute on Drug Abuse – R42 DA013867 Phase II

Principal Investigator: Craig F. Ferris, Project Period: 11/1/02 – 10/31/04, Total Costs: \$600,000

Gradient Coil to Enhance MRI Research in Mental Illness

National Institute of Mental Health – R42 MH064970 Phase II

Principal Investigator: Craig Ferris, Project Period: 6/1/04 – 5/30/06, Total Cost \$600,000

Neurobehavioral Effects of MDMA in Adolescent Monkeys

National Institute on Drug Abuse - 1R01 DA19158-01

Principal Investigator: Craig F. Ferris, Project Period: 12/01/04 – 11/30/09, Total Costs: \$3,200,000

Estrogenic Regulation of Cocaine Sensitization

NIH/Specialized Neuroscience Research Programs (PI, Garcia-Arraras)

NIH/5 U54 NS39405

Principal Investigator Annabell Segarra; Mentor Craig F. Ferris

Project periods 01/01/05 – 12/31/09 Total Directs – \$500,000

NCI Center Grant

U54CA151881-01

Principle Investigator Vladimir Torchilin

Imaging Core PI Craig Ferris

Project Period 10/1/2010 – 9/31/2015 Total Cost - \$737,280

Drug Discovery for the Treatment of Autism

Research Agreement (Ferris) \$800,000 11/01/2010 – 10/30/2012

Pfizer

Drug Discovery for the Treatment of Schizophrenia

Research Agreement (Ferris) \$350,000 01/07/2011- 12/30/2012

Sunovium

Screening New Therapeutics for the Treatment of PTSD

R41MH093049-01 (Simon) \$78,000 06/01/2011 – 05/31/2012

NIH/NIMH (Subaward – Ferris)

Drug Discovery for Treatment of Pain

Research Agreement (Ferris) \$80,000 08/01/2011 – 07/30/2013

Vertex Pharmaceuticals

Drug Discovery for Treatment of Huntington's Disease

Research Agreement (Ferris) \$75,000 05/01/2013 – 09/30/2013

CHDI Foundation

Sex Steroids and Cognition: The Marmoset as a New Primate Model

R21MH091492-01 (Lacreuse) \$72,000 04/07/2011 – 03/31/2013

NIH/NIMH (Subaward – Ferris)

Drug Discovery for the Treatment of Pain

Research Agreement (Ferris) \$48,000 12/01/2012 – 09/31/2013

Cubist Pharmaceuticals

Drug Discovery for the Treatment of Alzheimer's

Research Agreement (Ferris) \$120,000 07/1/2013 - 03/30/2015

Lundbeck Pharmaceuticals

Developmental Consequences of Birth Interventions

1P01HD075750-1 (Carter) Total: \$1,065,000 04/01/2014 - 03/31/2019

NICHD Project # 2 and Core 2 - Imaging

NIH Blueprint Program for Enhancing Neuroscience Diversity through Undergraduate ResearchExperiences (PI Kamangar), Virtual Imaging (Subaward - Ferris)

Proposal Period 11/1/14 - 0/30/2019

Total Cost \$1,097,876

Tier 3 Award, Provost's Office, Advanced Biosensors in Social/Affective Neuroscience (Ferris)

Proposal Period 3/27/2015 – 2/31/2016

Total Cost \$150,000

Drug Discovery for the Orphan Diseases

Research Agreement (Ferris)

Alexion Pharmaceuticals - Project Period 07/01/2015 – 12/30/2015 Total Cost \$60,000

Cutting-Edge Basic Research Awards

(CEBRA) NIDA (R21) (PIs Sridhar, Ferris)

Proposal Period 09/01/2016 – 08/31/2018 Total Cost \$386,250

Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magnetic Resonance Imaging Contrast Agent for Diagnosis of Renal Failure.

SBIR R44 DK100205-02 (PI Sitharaman)

Subaward: (Ferris)

Proposal Period 06/1/2016 – 5/31/2017 Total Cost \$50,000

Drug Discovery for the Alzheimer's

Research Agreement (Ferris)

Ironwood Pharmaceuticals - Project Period 07/01/2016 – 12/30/2016 Total Cost \$40,000

Dietary Fat Ratio's Influence on Adolescent Depression - A Nonhuman Primate Model,

R01 NIMH/NICHD, (PI Ziegler)

Subaward (Ferris)

Proposal Period 08/01/2016- 07/31/2022 Total Cost \$92,553

Developmental and Sex-Dependent Targets for Prevention after Early Life Stress

NIMH/NIH R01 PI Heather Brenhouse

Co-investigator (Ferris, Year 1)

Proposed Period 7/1/16 – 6/31/2017 Total Cost \$85,000

Imaging and Preclinical Drug Discovery

Fee for Service Contracts through Ekam Imaging

Multiple Projects, Period 2020 – 2023 Total Cost \$1,090,000

Direct CNS Delivery System for BDNF AntagoNATs using Heterotopic MucosalGrafting for the Treatment of Parkinson's Disease

1R01NS108968-01 (PI Bleier)

Subaward (Amiji, Ferris)

Proposal Period 01/01/2019 – 12/31/2023 Total \$1,279,394

A New Drug to Prevent the Effects of mild TBI/Concussion

Army Medical Research and Materiel Command (AMRMC)

HT94252410617 (PI Brownstein)

Subaward (Ferris)

Proposal Period 07/01/2024 – 06/30/2026 Directs \$354,231 Total \$565,000

PUBLICATIONS Over 300 peer-reviewed publications, commentaries and book chapters, more than 16,500+

citations and an H-index of 71 (Google Scholar 1/5/2025).

RESEARCH PAPERS

1. Passo, S.S., J.R. Thornborough and **C.F. Ferris**. Functional analysis of dopaminergic innervation of the neurohypophysis. American Journal of Physiology 241: E186-E190 (1981).
2. **Ferris, C.F.**, R.H. Hammer and S.E. Leeman. Elevation of plasma neurotensin during lipid perfusion of rat small intestine. Peptides 2: 263-266 (1981).
3. Aronin, N., R.E. Carraway, **C.F. Ferris**, R.A. Hammer and S.E. Leeman. The stability and metabolism of intravenously administered neurotensin in the rat. Peptides 3: 637-642 (1982).
4. **Ferris, C.F.**, J.X. Pan, E.A. Singer, N.D. Boyd and S.E. Leeman. Evaluation of neurotensin in the central regulation of luteinizing hormone release. In: Neurotensin, A Brain and Gastrointestinal Peptide. (Nemeroff, C.B., Prange, A.J., eds.) New York 400: 379-380 (1982).
5. **Ferris, C.F.**, R.E. Carraway and S.E. Leeman. Lipid stimulation of neurotensin release from rat small intestine. In: Neurotensin, A Brain and Gastrointestinal Peptide. (Nemeroff, C.B., Prange, A.J. Jr., eds) New York 400: 433-435 (1982).
6. Carraway, R.E. and **C.F. Ferris**. Isolation, biological and chemical characterization and synthesis of a neurotensin-related hexapeptide from chicken intestine. Journal of Biological Chemistry 258: 2475-2479 (1983).
7. **Ferris, C.F.**, J.X. Pan, E.A. Singer, N.D. Boyd, R.E. Carraway and S.E. Leeman. Stimulation of LH release after stereotaxic microinjection of neurotensin in the medial preoptic area of rats. Neuroendocrinology 38: 145-151 (1984).
8. Albers, H.E., **C.F. Ferris**, S.E. Leeman and B.D. Goldman. Avian pancreatic polypeptide phase-shifts hamster circadian rhythms when microinjected into the suprachiasmatic region. Science 223: 833-835 (1984).
9. **Ferris, C.F.**, H.E. Albers, S.M. Weslowski, B.D. Goldman and S.E. Leeman. Microinjection of vasopressin into a discrete hypothalamic site triggers a complex stereotypic behavior in golden hamsters. Science 224: 521-523 (1984).
10. Albers, H.E. and **C.F. Ferris**. Neuropeptide Y: role in light-dark cycle entrainment of hamster circadian rhythms. Neuroscience Letters 50: 163-168 (1984).
11. **Ferris, C.F.**, M.J. Armstrong, J.K. George, C.A. Stevens, R.E. Carraway and S.E. Leeman. Alcohol and fatty acid stimulation of neurotensin release from rat small intestine. Endocrinology 116: 1133-1138 (1985).
12. **Ferris C.F.**, J. Pollock, H.E. Albers, and S.E. Leeman. Inhibition of flank-marking behavior in golden hamsters by microinjection of a vasopressin antagonist into the hypothalamus. Neuroscience Letters 55: 239-243 (1985).
13. **Ferris, C.F.**, R.E. Carraway, R.A. Hammer and S.E. Leeman. Release and degradation of neurotensin

during perfusion of rat small intestine with lipid. Regulatory Peptides 12: 101-111 (1985).

14. Carraway, R.E., E.A. Singer, **C.F. Ferris** and S.P. Mitra. Generation of immunoreactive neurotensin(s) and enkephalin(s) by pepsin-treatment of plasma. Proceedings of the International Kinin Symposium, (1985).
15. Armstrong, M.J., **C.F. Ferris** and S.E. Leeman. Neurotensin increases the translocation of ³H-oleic acid from the intestinal lumen into lymph of rats. In: Regulatory Peptides, Mode of Action on Digestive, Nervous and Endocrine Systems, INSERM Symposium, vol 25. Edited by S. Bonfils, Elsevier Science Publishers, The Netherlands, pp 291-298 (1985).
16. Albers, H.E. and **C.F. Ferris**. Behavioral effects of vasopressin and oxytocin within the medial preoptic area of the golden hamster. Regulatory Peptides 12: 257-260 (1985).
17. **Ferris, C.F.** S. Parker, M.J. Armstrong and S.E. Leeman. Inhibition of neurotensin release by a cyclic hexapeptide analog of somatostatin. Peptides 6: 945-948 (1985).
18. **Ferris, C.F.**, R.E. Carraway, K. Brandt and S.E. Leeman. Chromatographic and immunochemical characterization of neurotensin in cat adrenal gland and its release during splanchnic nerve stimulation. Neuroendocrinology 43: 352-358 (1986).
19. Albers, H.E., J. Pollock, W.H. Simmons and **C.F. Ferris**. A V1-like receptor mediates vasopressin induced flank marking behavior within the hamster hypothalamus. Journal of Neuroscience 6: 2085-2089 (1986).
20. Carraway, R.E., S.P. Mitra and **C.F. Ferris**. Pepsin treatment of mammalian plasma generates immunoreactive and biologically active neurotensin-related peptides in micromolar concentrations. Endocrinology 119: 1519-1526 (1986).
21. **Ferris, C.F.**, D.M. Meenan and H.E. Albers. Microinjection of kainic acid into the hypothalamus of golden hamsters prevents vasopressin-dependent flank marking behavior. Neuroendocrinology 44: 112-116 (1986).
22. Armstrong, M.J., M.C. Parker, **C.F. Ferris** and S.E. Leeman. Neurotensin stimulates [³H]oleic acid translocation across rat small intestine. American Journal of Physiology 251: G823-G829 (1986).
23. **Ferris, C.F.**, D.M. Meenan, J.F. Axelson, and H.E. Albers. A vasopressin antagonist can reverse dominant/subordinate behavior in hamsters. Physiology and Behavior 38: 135-138 (1986).
24. **Ferris, C.F.**, J. George, and H.E. Albers. Circadian rhythm in neurotensin levels in rat small intestine. Regulatory Peptides 15: 285-292 (1986).
25. Albers, H.E. and **C.F. Ferris**. Role of the flank gland in vasopressin induce scent marking behavior in the hamster. Brain Research Bulletin 17: 387-389 (1986).
26. George, J., H.E. Albers, R.E. Carraway and **C.F. Ferris**. Neurotensin levels in the hepatic-portal circulation are inversely related to the circadian feeding cycle in rats. Endocrinology 121: 7-13 (1987).

27. Marshak, D.W., R.E. Carraway and **C.F. Ferris**. Characterization of immunoreactive substance P and neurotensin in the goldfish retina. Experimental Eye Research 44: 839-848 (1987).
28. **Ferris, C.F.**, J.F. Axelson, L. Shinto, and H.E. Albers. Scent marking and the maintenance of dominant/subordinate status in male golden hamster. Physiology and Behavior 40: 661-664 (1987).
29. Albers, H.E., N. Minamitani, E. Stopa, and **C.F. Ferris**. Light selectively alters vasoactive intestinal peptide- and peptide histidine isoleucine- immunoreactivity within the rat suprachiasmatic nucleus. Brain Research 437: 189-192 (1987).
30. Albers, H.E., S.Y. Liou, and **C.F. Ferris**. Testosterone alters the behavioral sensitivity to arginine vasopressin within the medial preoptic-anterior hypothalamus of the hamster. Brain Research 456: 382-386 (1988).
31. **Ferris, C.F.**, E. Singer, D.M. Meenan and H.E. Albers. Inhibition of vasopressin-stimulated flank marking behavior by V1-receptor antagonists. European Journal of Pharmacology 154: 153-159 (1988).
32. **Ferris, C.F.**, J.F. Axelson, A.M. Martin, and L. Roberge. Vasopressin immunoreactivity in the anterior hypothalamus is altered by aggressive interactions between hamsters. Neuroscience 29(3):675-683, (1989).
33. Alexander, M.J., P.D. Mahoney, **C.F. Ferris**, R.E. Carraway and S.E. Leeman. Evidence that neurotensin participates in the central regulation of the preovulatory surge of luteinizing hormone in the rat. Endocrinology 124: 783-788 (1989).
34. Potegal, M. and **C.F. Ferris**. Intraspecific aggression in male hamsters is inhibited by vasopressin receptor antagonists. Aggressive Behavior 15:311-320, (1990).
35. **Ferris, C.F.**, R.W. Irvin, M. Potegal and J.F. Axelson. Kainic acid lesion of vasopressinergic neurons in the hypothalamus disrupts flank marking behavior in golden hamsters. Journal of Neuroendocrinology 2:123-129, (1990).
36. **Ferris, C.F.** K. Muraki, R.E. Carraway. Exocrine secretion and processing of pro-xenopsin in rat gastric lumen. American Journal of Physiology 258:G419-G425 (1990).
37. **Ferris, C.F.**, L. Gold, G.J. DeVries and M. Potegal. Evidence for a functional anatomical relationship between the lateral septum and the hypothalamus in the control of vasopressin dependent flank marking behavior in golden hamsters. Journal of Comparative Neurology 293:476-485 (1990).
38. Mahoney, P.D., E.T. Koh, R.W. Irvin and **C.F. Ferris**. Computer-aided mapping of vasopressin neurons in the hypothalamus of the male golden hamster: Evidence of magnocellular neurons that do not project to the neurohypophysis. Journal of Neuroendocrinology 2:113-122 (1990).
39. Szot, P., **C.F. Ferris**, and D.M. Dorsa. Localization of ³H-arginine-vasopressin binding sites in the CNS of the golden hamster. Neuroscience Letters 119:215-218 (1990).

40. Irvin, R.W., P. Szot, D.M. Dorsa, M. Potegal, and **C.F. Ferris**. Vasopressin in the septal area of the golden hamster controls scent marking and grooming. Physiology and Behavior 48:693-699 (1990).
41. Albers, H.E., C.M. Rowland and **C.F. Ferris**. Arginine-vasopressin immunoreactivity is not altered by photoperiod or gonadal hormones in the Syrian hamster (Mesocricetus auratus). Brain Research 539:137-142 (1990).
42. **Ferris, C.F.**, J.K. George, G. Eastwood, M. Potegal and R.E. Carraway. Plasma levels of human neurotensin: methodological and physiological considerations. Peptides 12:215-220 (1991).
43. Huhman, K.L., T.O. Moore, **C.F. Ferris**, E.W. Mougey and J.L. Meyerhoff. Acute and repeated exposure to social conflict in male golden hamsters: Increases in plasma POMC-peptides and cortisol and decreases in plasma testosterone. Hormones and Behavior 25:206-216 (1991).
44. Hayden-Hixson, D.M., and **C.F. Ferris**. Cortisol exerts site-, context-, and dose-specific effects on the agonistic behaviors of male golden hamsters. Journal of Neuroendocrinology 3:613-622 (1991).
45. Hayden-Hixson, D.M., and **C.F. Ferris**. Steriod-specific regulation of agonistic behavior in the anterior hypothalamus of male golden hamsters Physiology and Behavior 50:793-799 (1991).
46. **Ferris, C.F.** K.B. Foote, H.M. Meltser, M.G. Plenby, K.L. Smith, and T. Insel. Oxytocin in the amygdala increases maternal aggression In: Oxytocin in Maternal, Sexual and Social Behavior, Eds C.A. Pederson, J. Caldwell, New York Academy of Sciences 652:468-469 (1992).
47. Delville, Y. and **C.F. Ferris**. Existence of sexual dimorphism in vasopressin binding in the area of the ventromedial nucleus of the hypothalamus in hamsters. In: Oxytocin in Maternal, Sexual and Social Behavior, Eds C.A. Pederson, J. Caldwell, New York Academy of Sciences 652: 470-471 (1992).
48. **Ferris, C.F.**, C.G. Pilapil, D. Hayden-Hixson, R.G. Wiley and E.T. Koh. Evidence for functionally and anatomically distinct populations of vasopressinergic magnocellular neurons in the golden hamster. Journal of Neuroendocrinology 4:193-205 (1992).
49. Delville, Yvon, C. Stires, and **C.F. Ferris**. Distribution of corticotropin-releasing hormone immunoreactivity in golden hamster brain. Brain Research Bulletin 29:681-684 (1992).
50. **Ferris, C.F.**, Y. Delville, Z. Gronka, J. Lubner-Narod and T.R. Insel. An iodinated vasopressin antagonist blocks flank marking and selectively labels neural binding sites in golden hamsters. Physiology and Behavior 54:737-747 (1993).
51. **Ferris, C.F.**, Y. Delville, R.W. Irvin, and M. Potegal. Septo-hypothalamic organization of stereotypic behavior controlled by vasopressin in golden hamsters. Physiology and Behavior 55:755-759 (1994).
52. Delville, Y., E.T. Koh, and **C.F. Ferris**. Sexual differences in the magnocellular vasopressinergic system in golden hamsters. Brain Research Bulletin 33:535-540 (1994).
53. Wang, Z-X, **C.F. Ferris**, and G.J. De Vries. The role of septal vasopressin innervation in paternal

- behavior in prairie voles (*Mecrotus ochrogaster*). Proceedings of the National Academy of Sciences (USA) 91:400-404 (1994).
54. **Ferris, C.F.** and Y. Delville. Vasopressin and serotonin interactions in the control of agonistic behavior. Psychoneuroendocrinology 19:593-601 (1994).
 55. Delville, Y., Mansour, K.M., Yules, B. Quan E.W.. and **C.F. Ferris**. Postnatal development of the vasopressinergic system in golden hamsters. Developmental Brain Research, 81: 230-239(1994).
 56. Insel, T.R., Wang, Z.X., and **C.F. Ferris**. Brain vasopressin receptor distribution in monogamous and polygynous voles. Journal of Neuroscience, 14(9): 5381-5392 (1994).
 57. **Ferris, C.F.**, Y. Delville, M.A. Miller, D.M. Dorsa, G.J. DeVries. Distribution of small vasopressinergic neurons in golden hamsters. Journal of Comparative Neurology, 360:589-598 (1995).
 58. Delville, Y. and **C. F. Ferris**. Sexual differences in vasopressin receptor binding within the ventrolateral hypothalamus in golden hamsters. Brain Research 681:91-96 (1995)
 59. Delville, Y., L.S. Conklin, and **C.F. Ferris**. Differential expression of vasopressin receptor binding in the hypothalamus during lactation in golden hamsters. Brain Research 689:147-150 (1995).
 60. Delville, Y., K.M. Mansour, and **C.F. Ferris**. Serotonin blocks vasopressin-facilitated offensive aggression: interactions within the ventrolateral hypothalamus of golden hamsters. Physiology and Behavior 59:813-816 (1995).
 61. Delville, Y., K.M. Mansour, and **C.F. Ferris**. Testosterone facilitates aggression by modulating vasopressin receptors in the hypothalamus. Physiology and Behavior, 60:25-29 (1996).
 62. **Ferris, C.F.**, Y. Delville, J. A. Brewer, B. Yules, K.M. Mansour, C.F. Ferris. Vasopressin and the developmental onset of flank marking in golden hamsters. Journal of Neurobiology 30:192-204 (1996).
 63. Potegal, M, **C.F. Ferris**, M. Hebert, J. Meyerhoff, L. Skaredoff. Attack priming in female Syrian golden hamsters is mediated by a c-fos coupled process within the corticomedial amygdala. Neuroscience 75:869-880 (1996).
 64. **Ferris, C.F.** Serotonin inhibits vasopressin facilitated aggression in the Syrian hamster. In: *Understanding Aggressive Behavior in Children* (C.F. Ferris and T. Grisso, eds) New York Academy of Sciences, New York, N.Y. 794:98-103 (1996).
 65. **Ferris, C.F.** and J. Brewer. Adolescent stress alters ethanol ingestion and agonistic behavior in male golden hamsters. In: *Understanding Aggressive Behavior in Children* (C.F. Ferris and T. Grisso, eds) New York Academy of Sciences, New York, N.Y. 794:348-351 (1996).
 66. Melloni, Jr. R.H. and **Ferris, C.F.** Adolescent anabolic steroid use and aggressive behavior. In *Understanding Aggressive Behavior in Children*, (C.F. Ferris and T. Grisso, eds.) New York Academy of Sciences, New York, N.Y. 794:372-375 (1996).

67. Melloni, R.H. Jr., D. F. Connor, P. T. Xuan Hang, R. J. Harrison, and **C.F. Ferris**. Anabolic-androgenic steroid exposure during adolescence facilitates aggressive behavior in golden hamsters. Physiology and Behavior 61:359-364 (1997).
68. Melloni, Jr. R.H., N. Aronin, J.J. Degennaro, **C.F. Ferris**, and R.J. Harrison. Restriction endonuclease fragmentation of cDNAs: A novel method of generating molecular probes for In Situ hybridization in brain. Journal of Histochemistry and Cytochemistry 45:755-763 (1997).
69. **Ferris, C.F.**, R. H. Melloni, Jr., G. Koppel, K. W. Perry, R.W.Fuller, and Y.Delville. Vasopressin/serotonin interaction in the anterior hypothalamus control aggressive behavior in golden hamsters. Journal of Neuroscience 17:4331-4340 (1997).
70. Coccaro, E.F., R.J. Kavoussi, R. L. Hauger, T. B. Cooper, and **C.F. Ferris**. Cerebrospinal fluid vasopressin levels correlates with aggression and serotonin function in personality-disordered subjects. Archives of General Psychiatry 55:708-714 (1998).
71. Delville, Y., G.J. De Vries, J.P. Roche, W.J. Schwartz and **C.F. Ferris**. Neural vasopressin innervation in golden hamsters: Distribution and origins; with special references to the suprachiasmatic nucleus. Behavioral Neuroscience 112:1486-1501 (1998).
72. **Ferris, C. F.**, K. Shtiegman, and J. A. King. Voluntary ethanol consumption in male adolescent hamsters increases testosterone and aggression. Physiology and Behavior 63:739-744 (1998).
73. Lahti, K, **C.F. Ferris**, L. Fuhai, C. Sotak, J.A. King. Imaging brain activity in conscious animals using functional MRI. Journal of Neuroscience Methods 82:75-83 (1998).
74. Delville, Y, R. H. Melloni, Jr. and **C.F. Ferris**. Behavioral and neurobiological consequences of social subjugation during puberty in golden hamsters. Journal of Neuroscience 18:2667-2672 (1998).
75. Miller, M.A., **C. F. Ferris**, P.E. Kolb. Absence of vasopressin expression by galanin neurons in the golden hamster: implications for species differences in extrahypothalamic vasopressin pathways. Molecular Brain Research 67:28-35 (1999).
76. Lahti, K, **C.F. Ferris**, L. Fuhai, C. Sotak, J.A. King. Comparison of evoked cortical activity in conscious and propofol anesthetized rats using functional MRI. Magnetic Resonance in Medicine 41:412-416 (1999).
77. **Ferris, C.F.**, T.Stolberg, Y. Delville. Serotonin regulation of offensive aggression in male golden hamsters. Behavioral Neuroscience 113:804-815 (1999).
78. **Ferris, C.F.**, Y. Delville, Bonigut, S., and M.A. Miller. Galanin antagonizes vasopressin-stimulated flank marking in male golden hamsters. Brain Research 832:1-6 (1999).
79. Delville, Y., DeVries, G, **Ferris, C. F.**, Neural connections of the anterior hypothalamus and agonistiic behavior in golden hamsters. Brain Behavior and Evolution 55:53-76 (2000).
80. King, J.A. R. Barkley, Y. Delville, and **C.F. Ferris**. Early androgen treatment decreases cognitive function and catecholamine innervation in an animal model of ADHD. Behavioral Brain Research

107:35-43 (2000).

81. **Ferris, C.F.** Adolescent stress and neural plasticity in hamsters: a vasopressin/serotonin model of inappropriate aggressive behavior. Experimental Physiology 85:85-90 (2000).
82. **Ferris, C.F.** CT Snowden, JA King, TQ Duong, TE Ziegler, K Ugurbil, R Ludwig, NJ Schultz-Darken, Z Wu, DP Olson JM Sullivan Jr. PL Tannenbaum and JT Vaughan. Functional imaging of brain activity in conscious monkeys responding to sexually arousing cues. NeuroReport 12:2231-2236 (2001).
83. **Ferris, C.F.** Rasmussen, M.F., T. Messenger, and G. Koppel. Vasopressin-dependent flank marking in golden hamsters is suppressed by drugs used in the treatment of obsessive-compulsive disorder. BMC Neuroscience 2(1):10 (2001).
84. King, J.A., Messenger, T., **Ferris, C.F.** Seed finding in golden hamsters: a potential animal model of anxiety. Neuropsychobiology 45:150-155 (2002).
85. Dickson, E.W., S.B. Bird, R.J. Gaspari, E.W. Boyer, **C.F. Ferris**. Diazepam inhibits organophosphate-induced central respiratory depression. Academy of Emergency Medicine 10:1-4 (2003).
86. Sicard, K. Q. Shen, M. Brevard, R. Sullivan, **C.F. Ferris**, J.A. King, and T.Q. Duong. Regional cerebral blood flow in conscious and anesthetized rats under basal and hypercapnic conditions: Implication for fMRI studies. Journal of Cerebral Blood Flow and Metabolism 23:472-481 (2003).
87. Brevard, M.E., T.Q. Duong, J.A. King, and **C.F. Ferris**. BOLD signal changes in fully conscious rats following hypercapnic challenge. Magnetic Resonance Imaging 21:995-1001 (2003).
88. Tenney, J.R., T.Q. Duong, J.A. King, R. Ludwig and **C.F. Ferris**. Corticothalamic modulation during absence seizures: A functional MRI approach. Epilepsia 44:1133-1140 (2003).
89. **Ferris, C.F.** Using an animal model to assess the long-term behavioral and biological consequences of adolescent abuse and exposure to alcohol. In: Roots of Mental Illness in Children eds J.A. King C.F. Ferris, I.I Lederhendler Annals of the New York Academy of Sciences 1008:69-78 (2003)
90. Rossi V. Messenger T., Peters D., **Ferris C.F.** and J. King. Prenatal nicotine exposure and behavior. Ann. N. Y. Acad. Sci. 1008:289-292 (2003).
91. **Ferris, C.F.** C.T. Snowden, J.A. King, J.M. Sullivan Jr, T.E. Ziegler, R. Ludwig, N.J. Schultz-Darken, Z. Wu, D.P. Olson. P.L. Tannenbaum, A. Einspanier, J. T. Vaughan and T.Q. Duong. Activation of neural pathways associated with sexual arousal in non-human primates. Journal of Magnetic Resonance Imaging 19:168-175(2004).
92. Ludwig R., G. Bogdanov, J.A. King., A. Allard, **C.F. Ferris**. A dual RF resonator system for high-field functional magnetic-resonance imaging of small animals. Journal of Neuroscience Methods 132:125-135 (2004).
- (1)
93. Lemdiasov, R., R. Ludwig, M. Brevard, **C.F. Ferris**. Design and implementation of a uniplanar

- gradient field coil for magnetic resonance imaging. Magnetic Resonance Engineering 20B:17-29 (2004).
94. Tenney, J.R., T.Q. Duong, J.A. King, and **C.F. Ferris**. Functional MRI of brain activity in a genetic rat model of absence seizures. Epilepsia 45:576-582 (2004).
 95. Febo M, A. Segarra, J. Tenney, R. Sullivan, M. Brevard, T.Q. Duong; **C. F. Ferris**. Imaging cocaine-induced changes in the reward system in conscious rats. Journal of Neuroscience Methods 139:167-176 (2004).
 96. Li, J., Y. Guo, F.A. Schroeder, R.A. Youngs, T.W. Schmidt, **C.F. Ferris**, C Konradi, S Akbarian. Antipsychotic drugs regulate chromatin structure in striatal neurons through cAMP-PKA and postsynaptic NMDA receptors. Journal of Neurochemistry 90:1117-1131 (2004).
 97. Snowdon CT, **Ferris CF**, King JA, Ziegler TE, Schultz-Darken NA, Olson DP. Noninvasive imaging of neural pathways activated by odors from ovulating female common marmosets. *Folia Primatol.* (Basel). 75 (suppl 1):222 (2004).
 98. Tenney J.R., M.E. Brevard, J.A. King, **C.F. Ferris**. fMRI of generalized absence seizures in conscious marmoset monkeys reveals corticothalamic activation. Epilepsia 45:1240-1247 (2004).
 99. Ziegler, T.E., N. J. Schultz-Darken, J.J. Scott, C.T. Snowdon, **C.F. Ferris**. Neuroendocrine response to female periovulatory odors depends upon social condition in male common marmosets, *Callithrix jacchus* Hormones and Behavior 47:56-64 (2005).
 100. King, J.A. T.S. Garelick, M. Brevard, W. Chen, T. Messenger, T.Q. Duong, **C.F. Ferris**. Acclimating fully conscious rats to restraint stress during magnetic resonance imaging. Journal of Neuroscience Methods 148:154-160 (2005).
 101. **Ferris, C.F.**, T. Messenger, R. Sullivan. Behavioral and neuroendocrine consequences of social subjugation across adolescence and adulthood. Frontiers in Zoology 22:7-17 (2005)
 102. Febo, M., **C.F. Ferris**, A.C. Segarra. Estrogen determines cocaine-induced neuroadaptations in female rats: evidence from *in vivo* functional imaging. Journal of Neuroscience 25:1132-1136 (2005).
 103. **Ferris, C.F.**, P. Kulkarni, M.J. Sullivan Jr., J.A. Harder, T.L. Messenger, M. Febo. Pup suckling is more rewarding than cocaine: Evidence from fMRI and 3D computational analyses. Journal of Neuroscience 25:149-156 (2005)
 104. Febo, M., Segarra, A.C., Nair, G., Schmidt, K., Duong, T.Q., **C.F. Ferris**. The neural consequences of repeated cocaine exposure revealed by functional MRI in awake rats. Neuropsychopharmacology 25:1132-1136 (2005).
 105. Febo, M., M. Numan, **C.F. Ferris**. Functional MRI shows oxytocin activates brain regions associated with mother-pup bonding during suckling. Journal of Neuroscience 25:11637-11644 (2005).
 106. **Ferris, C.F.**, M. Febo, F. Luo, K Schmidt, M. Brevard, P Kulkarni, T. Messenger, J. Harder, J.A. King. Functional magnetic resonance imaging in conscious animals: A new tool in behavior

- neuroscience research. Journal of Neuroendocrinology 18:307-318 (2006).
107. Brevard M., P. Kulkarni J.A. King, **C.F. Ferris**. Imaging the neural substrates involved in the genesis of generalized clonic seizures. Epilepsia 47:740-754 (2006).
 108. Brevard, M.E., J.S. Meyer, J. Harder, **C.F. Ferris**. Imaging brain activity in conscious monkeys following oral MDMA (“Ecstasy”) at a dose consumed in recreational drug use. Magnetic Resonance Imaging 24:707-714 (2006).
 109. Schmidt, K.F. M. Febo, Q. Shen, K. M. Sicard, **C. F. Ferris**, E. A. Stein, T.Q. Duong. Imaging changes in cerebral blood flow, blood oxygenation, and oxidative metabolism following systemic cocaine challenge in the anesthetized rat. Psychopharmacology 185:479-486 (2006).
 110. Sicard K.M., N. Henninger, M. Fisher, **C.F. Ferris** Differential recovery of multimodal MRI and behavior after transient focal cerebral ischemia in rats. Journal of Cerebral Blood Flow and Metabolism 26:1451-1462 (2006).
 111. **Ferris, C.F.**, S-F Lu, T. Messenger, C.D. Guillon, G.A. Koppel, M.J. Miller, N.D. Heindel, N.G. Simon. Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior. Pharmacology, Biochemistry and Behavior 83:169-174 (2006).
 112. Meyer, J.S., M.E. Brevard, B.J. Piper, S.F. Ali, **C.F. Ferris**. Neural effects of MDMA as determined by functional magnetic resonance imaging and magnetic resonance spectroscopy in awake marmoset monkeys. New York Academy of Sciences 1074:365-376 (2006).
 113. Sicard K.M., N. Henninger, M. Fisher, T.Q. Duong, **C.F. Ferris** Long-term changes of functional MRI-based brain function, behavioral status, and histopathology after transient focal cerebral ischemia in rats. Stroke 37:2593-2600 (2006).
 114. Snowdon.,C.T., T.E. Ziegler, N. J. Schultz-Darken **C.F. Ferris**. Social odors, sexual arousal, and pair bonding in primates. Philosophical Transactions of the Royal Society B: Biological Sciences 361:2079-2089 (2006).
 115. Guillon C., G.A. Koppel, M.J. Brownstein, M.O. Chaney, **C.F. Ferris**, S.-F. Lu, K.M. Faqbio, M.J. Miller, N.D. Heindel, D.C. Hunden, R.D. Cooper, S.W. Kaldor, J.J. Skelton, B.A. Dressman, M.P.Clay, M.I. Steinberg, R.F. Bruns, N.G. Simon. Azetidinones as vasopressin V1a antagonists. Bioorganic and Medicinal Chemistry 15:2054-2080 (2007).
 116. Luo, F., Z. Li, A. Pietrzykiowski, S. Treistman, J.A. King, **C.F. Ferris**. Confounding effects of volatile anesthesia on CBV assessment in rodent forebrain following ethanol challenge. Journal of Magnetic Resonance Imaging 26:557-563 (2007).
 117. Brevard M.E., **C.F. Ferris**. Response to “Historical Perspective on PTZ-Induced Seizures”. Epilepsia 48:846 (2007).
 118. Febo, M., **C.F. Ferris**. Development of cocaine sensitization before pregnancy affects subsequent maternal retrieval of pups and prefrontal cortical activity during nursing. Neuroscience 148:400-412 (2007).

119. Jensen P.S., E. Youngstrom, H. Steiner, R.L. Findling, R.E. Meyer, R.P. Malone, G.A. Carlson, E.F. Coccaro, M.D., M.G. Aman, J. Blair, D. Dougherty, **C.F Ferris**, L. Flynn, E. Green, K. Hoagwood, J. Hutchinson, T. Laughren, L.D. Leve, D.K. Novins, B. Vitiello. Consensus report: impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies. Journal of the American Academy of Child and Adolescent Psychiatry 46:309-322 (2007).
120. Prudom, S.L., C.A. Broz, N. Schultz-Darken, **C.F. Ferris**, C. Snowdon, T.E. Ziegler, Exposure to infant scent lowers serum testosterone in father common marmosets (*Callithrix jacchus*) Biology Letters: Animal behavior, published online (2008)
121. Febo M., T.L. Messenger-Stolberg, M. Numan, R S. Bridges, P. Kulkarni, **C.F Ferris**. Nursing stimulation is more than tactile sensation: It is a multisensory experience. Hormones and Behavior 54:330-339 (2008).
122. Simon N.G, C. Guillon, K Fabio, N.D. Heindel, S.F. Lu, M. Miller, **C.F. Ferris**, M.J. Brownstein, C. Garripa, G.A. Koppel. Vasopressin antagonists as anxiolytics and antidepressants: recent developments Recent Patents CNS Drug Discovery 2:77-93, 2008.
123. **Ferris C.F.** Functional magnetic resonance imaging and the neurobiology of vasopressin and oxytocin. Progress in Brain Research 170:305-320, 2008.
124. **Ferris C.F.**, T. Stolberg-Messenger, P. Kulkarni, M. Murugavel, R. Blanchard, D. C. Blanchard, M. Febo, M. Brevard, N.G. Simon, Imaging the neural circuitry and chemical control of aggressive motivation, BMC Neuroscience 13,9:111 2008.
125. Febo M, Shields J, **Ferris CF**, King JA. Oxytocin modulates unconditioned fear response in lactating dams: an fMRI study. Brain Research. 1302:183-93. 2009.
126. Nephew BC, Caffrey MK, Felix-Ortiz AC, **Ferris CF**, Febo M. Blood oxygen level-dependent signal responses in corticolimbic 'emotions' circuitry of lactating rats facing intruder threat to pups. European Journal of Neuroscience 30:934-945. 2009.
127. Febo M, Akbarian S, Schroeder FA, **Ferris C.F.** Cocaine-induced metabolic activation in cortico-limbic circuitry is increased after exposure to the histone deacetylase inhibitor, sodium butyrate. Neuroscience Letters. 465:267-71. 2009
128. Lee R, **Ferris C.F.**, Van de Kar LD, Coccaro EF. Cerebrospinal fluid oxytocin, life history of aggression, and personality disorder. Psychoneuroendocrinology. 34:1567-73. 2009
129. Kim DJ, King JA, Zuccarelli L, **Ferris C.F.**, Koppel GA, Snowdon CT, Ahn CH. Clavulanic acid: a competitive inhibitor of beta-lactamases with novel anxiolytic-like activity and minimal side effects. Pharmacology Biochemistry and Behavior 93:112-20. 2009
130. Luo F, Schmidt KF, Fox GB, **Ferris C.F.** Differential responses in CBF and CBV to cocaine as measured by fMRI: implications for pharmacological MRI signals derived oxygen metabolism assessment. Journal Psychiatric Research. 43:1018-24. 2009

131. Febo, M. A.C. Segarra, T.L. Stolberg, **C.F. Ferris**. BOLD signal response to cocaine varies with sexual receptivity in female rats. NeuroReport (in press) 2010.
132. **Ferris C.F.**, Stolberg T. Imaging the immediate non-genomic effects of stress hormone on brain activity. Psychoneuroendocrinology. 35:5-14. 2010
133. Gultepe, E., F.J. Reynoso, A. Jhaveri, P. Kulkarni, D. Nagesha, **C.F. Ferris**, M. Harisinghani, R.B. Campbell, S. Sridhar. Monitoring of magnetic targeting to tumor vasculature through MRI and biodistribution. Nanomedicine, 5:1173-1182, 2010.
134. Snowdon, C., N.J. Schultz-Darken, P.L. Tannenbaum, T.E. Ziegler, **C.F. Ferris**. Conditioned sexual arousal in a nonhuman primate. Hormones and Behavior 59:696-701, 2011.
135. Huh Y., Huh, M.S. Ju, H. Park, S. Han, Y-M. Bang, **C.F. Ferris**, G.A. Koppel, J.A. King, M.L. Kim, D.J. Kim, C.H. Ahn, M-S. Oh. Clavulanic acid protects neurons in pharmacological models of neurodegenerative diseases. Drug Development Research 71, 351–357, 2011.
136. Reynoso, F, E Gultepe, A Jhaveri, P Kulkarni, B Gershman, **CF Ferris**, R Campbell, and S Sridhar; TH-D-201C-08: Multi-Modal MRI SPECT and CT Imaging of Theranostic Nanoplatfroms: Medical Physics. 37, 3470 2011.
137. Fabio K., C. Guillon, C.J. Lacey, S.Lu, N.D. Heindel, **C.F. Ferris**, M. Placzek G. Jones, M.J. Brownstein, N. G. Simon, Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging. Bioorganic and Medicinal Chemistry 20:1337-45. 2012.
138. Patil V, Gada K, Panwar R, Varvarigou A, Majewski S, Weisenberger A, **Ferris C.F**, Tekabe Y, Khaw BA. Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates. Eur Journal Nuclear Medical Molecular Imaging 39:824-39, 2012.
139. Kulkarni P, Stolberg T, Sullivan JM, **Ferris CF**. Imaging evolutionarily conserved neural networks: preferential activation of the olfactory system by food-related odor. Behavioral Brain Research 230:201-207, 2012
140. Shamey JL, Kulkarni P, Meadowcroft M, Nedelman M, Alberini C, **Ferris CF**, Baxter M. Systemic administration of insulin-like growth factor 2 results in increased BOLD pharmacological MRI response in memory-related brain regions. Alzheimer's and Dementia 9:P159-P160, 2013
141. **Ferris CF**, Marella M, Smerkers B, Barchet T, Gershman B, Matsuno-Yage A, Yagi T: A Phenotypic Model Recapitulating the Neuropathology of Parkinson's Disease. Brain and Behavior 3:351-366, 2013.
142. Ganta S, Singh A, Rawal Y, Cacaccio J, Patel NR, Kulkarni P, **Ferris CF**, Amiji M, Coleman T, Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome

- multidrug resistance in ovarian cancer. Drug Delivery 5:1-13, 2014.
143. Lacreuse A, Chang J, Metevier CM, LaClair M, Meyer JS, **Ferris CF**. Oestradiol modulation of cognition in adult female marmosets (*Callithrix jacchus*). J Neuroendocrinology 26:296-309,2014.
144. Shah L, Kulkarni P, **Ferris CF**, Amiji MM. Analgesic efficacy and safety of DALDA peptide analog delivery to the brain using oil-in-water. Pharmacology Research. 3:2014.
145. Febo M, **Ferris CF**. Oxytocin and vasopressin modulation of the neural correlates of motivation and emotion: results from functional MRI studies in awake rats. Brain Research 2014 30: 2014
146. **Ferris CF**, Kulkarni P, Toddes S, Yee J, Kenkel W, Nedelman M. Studies on the Q175 Knock-in Model of Huntington's Disease Using Functional Imaging in Awake Mice: Evidence of Olfactory Dysfunction. Frontiers in Neurology. 5:94. 2014. PMID: 25071696
147. Yee JR, Kenkel W, Caccaviello JC, Gamber K, Simmons P, Nedelman M, Kulkarni P, **Ferris CF**. Identifying the integrated neural networks involved in capsaicin-induced pain using fMRI in awake TRPV1 knockout and wild-type rats. Frontier in Systems Neuroscience Feb 19;9:15. 2015 PMID:25745388.
148. Ganta S, Singh A, Kulkarni P, Keeler AW, Piroyan A, Sawant RR, Patel NR, Davis B, **Ferris CF**, O'Neal S, Zamboni W, Amiji MM, Coleman TP. EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy. Pharmacology Research [Epub ahead of print] 2015 PMID:25732960.
149. Kenkel WM, Yee JR, Porges SW, **Ferris CF**, Carter CS. Cardioacceleration in alloparents in response to stimuli from prairie vole pups: The significance of thermoregulation. Behavioral Brain Research [Epub ahead of print] 2015 PMID:25721742
150. Madularu D, Yee JR, Kenkel WM, Moore KA, Kulkarni P, Shams WM, **Ferris CF**, Brake WG. Integration of neural networks activated by amphetamine in females with different estrogen levels: A functional imaging study in awake rats. Psychoneuroendocrinology 2015 56:200-212. PMID:25827963
151. Kulkarni P, Kenkel W, Finklestein SP, Barchet TM, Ren J, Davenport M, Shenton ME, Kikinis Z, Nedelman M, **Ferris CF**. Use of Anisotropy, 3D Segmented Atlas, and Computational Analysis to Identify Gray Matter Subcortical Lesions Common to Concussive Injury from Different Sites on the Cortex. PLoS One. 2015 May 8;10(5):PMID:25955025
152. Madularu D, Kulkarni P, **Ferris CF**, Brake WG. Changes in brain volume in response to estradiol levels, amphetamine sensitization and haloperidol treatment in awake female rats. Brain Research. 2015 May 29 [Epub ahead of print] PMID:26032742
153. **Ferris CF**, Yee JR, Kenkel WM, Dumais KM, Moore K, Veenema AH, Kulkarni P, Perkybile AM, Carter CS. Distinct BOLD activation profiles following central and peripheral oxytocin

- administration in awake rats. Front Behavioral Neuroscience. 2015 Sep 17;9:245. PMID:26441574
154. Yee JR, Kenkel WM, Kulkarni P, Moore K, Perkeybile AM, Toddes S, Amacker JA, Carter CS, **Ferris CF**. BOLD fMRI in awake prairie voles: A platform for translational social and affective neuroscience. NeuroImage. 2016 Sep;138:221-32. PMID:27238725
155. Madularu D, Kulkarni P, Yee JR, Kenkel WM, Shams WM, **Ferris CF**, Brake WG. High estrogen and chronic haloperidol lead to greater amphetamine-induced BOLD activation in awake, amphetamine-sensitized female rats. Hormones and Behavior. 2016 Jun;82:56-63. PMID: 27154458
156. Kenkel WM, Yee JR, Moore K, Madularu D, Kulkarni P, Gamber K, Nedelman M, **Ferris CF**. Functional magnetic resonance imaging in awake transgenic fragile X rats: evidence of dysregulation in reward processing in the mesolimbic/habenular neural circuit. Translational Psychiatry. 2016 Mar 22;6:e763.PMID:27003189
157. Moore K, Madularu D, Iriah S, Yee JR, Kulkarni P, Darcq E, Kieffer BL, **Ferris CF**. BOLD Imaging in Awake Wild-Type and Mu-Opioid Receptor Knock-Out Mice Reveals On-Target Activation Maps in Response to Oxycodone. Front Neuroscience. 2016 10:471.PMID: 27857679
158. Febo M, Blum K, Badgaiyan RD, Perez PD, Colon-Perez LM, Thanos PK, **Ferris CF**, Kulkarni P, Giordano J, Baron D, Gold MS. Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z. PLoS One. 2017 PMID:28445527
159. Dumais KM, Kulkarni PP, **Ferris CF**, Veenema AH. Sex differences in neural activation following different routes of oxytocin administration in awake adult rats. Psychoneuroendocrinology. 2017 Apr 7;81:52-62. PMID:28412582
160. Kikinis Z., M. Muehlmann, O. Pasternak, S. Peled, P. Kulkarni, **C.F. Ferris**, S. Bouix, Y. Rathi, I. K. Koerte, S. Pieper, A. Yarmarkovich, C.L. Porter, B.S. Kristal, M.E. Shenton. Diffusion imaging of mild traumatic brain injury in the impact accelerated rodent model: A pilot study. Brain Injury Published online: 19 Jun 2017 PMID: 28627942
161. **Ferris CF**, Kulkarni P, Yee JR, Nedelman M, de Jong IEM. The Serotonin Receptor 6 Antagonist Idalopirdine and Acetylcholinesterase Inhibitor Donepezil Have Synergistic Effects on Brain Activity-A Functional MRI Study in the Awake Rat. Front Pharmacol. 2017 12;8:279. PMID:28659792
162. Gharagouzloo CA, Timms L, Qiao J, Fang Z, Nneji J, Pandya A, Kulkarni P, van de Ven AL, **Ferris C.F**, Sridhar S. Quantitative vascular neuroimaging of the rat brain using superparamagnetic nanoparticles: New insights on vascular organization and brain function. Neuroimage. 2017 Sep 6. PMID:28889004
163. Madularu D, Yee JR, Kulkarni P, **Ferris C.F**. System-specific activity in response to Δ^9 - tetrahydrocannabinol: A functional magnetic resonance imaging study in awake male rats

Eur J Neurosci. 2017 Oct 23. PMID:29057576.

164. Terranova JI, **Ferris CF**, Albers HE, Sex Differences in the Regulation of Offensive Aggression and Dominance by Arginine-Vasopressin. Front Endocrinol 2017 14;8:308. PMID:29184535.
165. Upponi, J. R. Jerajani, K. Nagesha, D. K. Kulkarni, P. Sridhar, S. **Ferris, CF**. Torchilin, V. P. Polymeric micelles: Theranostic co-delivery system for poorly water-soluble drugs and contrast agents. Biomaterials 2018, 170 26-36 PMID: 5918157.
166. **Ferris, C. F.**, Morrison, T. R., Iriah, S., Malmberg, S., Kulkarni, P., Hartner, J. C., Trivedi, M. Evidence of Neurobiological Changes in the Presymptomatic PINK1 Knockout Rat. Journal of Parkinson's Disease 2018 PMID: 29710734
167. Sinkevicius, K. W., Morrison, T. R., Kulkarni, P., Cagliostro, M. K. C., Iriah, S., Malmberg, S., Sabrick, J., Honeycutt, J. A., Askew, K. L., Trivedi, M., **Ferris, C.F.** RNaseT2 knockout rats exhibit hippocampal neuropathology and deficits in memory. Dis Model Mech. 2018 PMID: 2975228
168. Mitra, R., J. Qiao, M. Sudharsan, G. L. O'Neil, B. Ritchie, P. Kulkarni, S. Sridhar, A. van de Ven, E. M. C. Kemmerling, **C.F. Ferris**, J. A. Hamilton, E.E. Ebong. The comparative effects of high fat diet or disturbed blood flow on glycocalyx integrity and vascular inflammation. Transl Med Commun. 2018; PMID: 30957020
169. Morrison TR, Kulkarni P, Cai X, Iriah S, Aggarwal D, Lu SF, Simon NG, Madularu D, **Ferris CF**. Treating Head Injury using a Novel Vasopressin 1a Receptor Antagonist. Neurosci Lett. 2019 PMID:31639422
170. Kulkarni P, Morrison TR, Cai X, Iriah S, Simon N, Sabrick J, Neuroth L, **Ferris CF**. Neuroradiological Changes Following Single or Repetitive Mild TBI. Front Syst Neurosci. 2019 PMID:31427931
171. **Ferris CF**, Nodine S, Pottala T, Cai X, Knox TM, Fofana FH, Kim S, Kulkarni P, Crystal JD, Hohmann AG. Alterations in brain neurocircuitry following treatment with the chemotherapeutic agent paclitaxel in rats. Neurobiol Pain. 2019 PMID:31223138
172. Kenkel WM, Perkeybile AM, Yee JR, Pournajafi-Nazarloo H, Lillard TS, Ferguson EF, Wroblewski KL, **Ferris CF**, Carter CS, Connelly JJ. Behavioral and epigenetic consequences of oxytocin treatment at birth. Sci Adv. 2019 PMID:31049395
173. Yadav S, Pawar G, Kulkarni P, **Ferris CF**, Amiji M. CNS Delivery and Anti-Inflammatory Effects of Intranasally Administered Cyclosporine-A in Cationic Nanoformulations. J Pharmacol Exp Ther. 2019 PMID:30591529
174. Iriah SC, Trivedi M, Kenkel W, Grant SE, Moore K, Yee JR, Madularu D, Kulkarni P, **Ferris CF**. Oxycodone Exposure: A Magnetic Resonance Imaging Study in Response to Acute and Chronic Oxycodone Treatment in Rats. Neuroscience. 2019 PMID:30550747

175. Cai X, Qiao J, Knox T, Iriah S, Kulkarni P, Madularu D, Morrison T, Waszczak B, Hartner JC, **Ferris CF**. In search of early neuroradiological biomarkers for Parkinson's Disease: Alterations in resting state functional connectivity and gray matter microarchitecture in PINK1 $-/-$ rats. Brain Res. 2019 PMID:30389398
176. **CF Ferris**, X. Cai, J. Qiao, B. Switzer, J. Baun, T. Morrison, S. Iriah, D. Madularu, K. W. Sinkevicius, P. Kulkarni Life without a brain: Neuroradiological and behavioral evidence of neuroplasticity necessary to sustain brain function in the face of severe hydrocephalus Science Report 2019; PMCID: PMC6848215
177. Cai X, Qiao J, Kulkarni P, Harding IC, Ebong E, **Ferris CF**. Imaging the effect of the circadian light-dark cycle on the glymphatic system in awake rats. Proc Natl Acad Sci U S A. 2019 PMID:31848247.
178. Morrison TR, Kulkarni P, Cai X, Iriah S, Aggarwal D, Lu SF, Simon NG, Madularu D, **Ferris CF**. Treating head injury using a novel vasopressin 1a receptor antagonist. Neuroscience Letters 2020 PMID:31639422
179. Carter CS, Kenkel WM, MacLean EL, Wilson SR, Perkeybile AM, Yee JR, **Ferris CF**, Nazarloo HP, Porges SW, Davis JM, Connelly JJ, Kingsbury MA. Is Oxytocin "Nature's Medicine"? Pharmacological Reviews 2020 PMID:32912963
180. Honeycutt JA, Demaestri C, Peterzell S, Silveri MM, Cai X, Kulkarni P, Cunningham MG, **Ferris CF**, Brenhouse HC. Altered corticolimbic connectivity reveals sex-specific adolescent outcomes in a rat model of early life adversity. Elife 2020 PMID:31958061
181. Qiao J, Lawson CM, Rentrup KFG, Kulkarni P, **Ferris CF**. Evaluating blood-brain barrier permeability in a rat model of type 2 diabetes. J Translational Medicine 2020 PMID: 32580725
182. Ziegler TE, Kulkarni P, Ash H, Cai X, Elizabeth Mayerand M, Rauch B, **Ferris CF**. Novel imaging technology and procedures for studying brain function in preadolescent awake marmosets. J Neuroscience Methods 2020 PMID:32580061
183. Farra YM, Eden MJ, Coleman JR, Kulkarni P, **Ferris CF**, Oakes JM, Bellini C. Acute neuroradiological, behavioral, and physiological effects of nose-only exposure to vaporized cannabis in C57BL/6 mice. Inhalation Toxicology 2020 PMID:32475185
184. Kulkarni P, Grant S, Morrison TR, Cai X, Iriah S, Kristal BS, Honeycutt J, Brenhouse H, Hartner JC, Madularu D, **Ferris CF**. Characterizing the human APOE epsilon 4 knock-in transgene in female and male rats with multimodal magnetic resonance imaging. Brain Research 2020 PMID:32745658
185. Ortiz R, Yee JR, Kulkarni PP, Solomon NG, Keane B, Cai X, **Ferris CF**, Cushing BS. Differences in Diffusion-Weighted Imaging and Resting-State Functional Connectivity Between Two Culturally Distinct Populations of Prairie Vole. Biological Psychiatry Cognitive Neuroscience Neuroimaging. 2020 PMID: 33239258

186. Kulkarni P, Bhosle MR, Lu SF, Simon NS, Iriah S, Brownstein MJ, **Ferris CF**. Evidence of early vasogenic edema following minor head impact that can be reduced with a vasopressin V1a receptor antagonist. Brain Research Bulletin 2020 PMID: 33053434
187. Lawson CM, Rentrup KFG, Cai X, Kulkarni PP, **Ferris CF**. Using multimodal MRI to investigate alterations in brain structure and function in the BBZDR/Wor rat model of type 2 diabetes Animal Model Experimental Medicine 2020 PMID:33532703
188. **Ferris CF**. Rethinking the Conditions and Mechanism for Glymphatic Clearance Frontiers Neuroscience 2021 PMID:33897347
189. Emam S, Nasrollahpour M, Colarusso B, Cai X, Grant S, Kulkarni P, Ekenseair A, Gharagouzloo C, **Ferris CF**, Sun NX. Detection of presymptomatic Alzheimer's disease through breath biomarkers. Alzheimers Dementia (Amst). 2020 PMID: 33088894
190. Sadaka AH, Ozuna AG, Ortiz RJ, Kulkarni P, Johnson CT, Bradshaw HB, Cushing BS, Li AL, Hohmann AG, **Ferris CF**. Cannabidiol has a unique effect on global brain activity: a pharmacological, functional MRI study in awake mice. J Translational Medicine. 2021 PMID: 34030718
191. Kulkarni P, Bens N, Karia DK, **Ferris CF**. Whole brain in vivo neuropathology: imaging site-specific changes in brain structure over time following trimethyltin exposure in rats. Toxicol Lett. 2021 PMID: 34600096.
192. Leaston J, **Ferris CF**, Kulkarni P, Chandramohan D, van de Ven AL, Qiao J, Timms L, Sepulcre J, El Fakhri G, Ma C, Normandin MD, Gharagouzloo C. Neurovascular imaging with QUTE-CE MRI in APOE4 rats reveals early vascular abnormalities. PLoS One. 2021.PMID: 34449808
193. Arezoumandan S, Cai X, Kulkarni P, Davis SA, Wilson K, **Ferris CF**, Cairns NJ, Gitcho MA. Hippocampal neurobiology and function in an aged mouse model of TDP-43 proteinopathy in an APP/PSEN1 background. Neurosci Lett. 2021.PMID: 34090937
194. Alkisar I, Miller AR, Hohmann AG, Sadaka AH, Cai X, Kulkarni P, **Ferris CF**. Inhaled Cannabis Suppresses Chemotherapy-Induced Neuropathic Nociception by Decoupling the Raphe Nucleus: A Functional Imaging Study in Rats. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 .PMID: 33622657
195. Demaree JL, Ortiz RJ, Cai X, Aggarwal D, Senthilkumar I, Lawson C, Kulkarni P, Cushing BS, **Ferris CF**. Exposure to methylphenidate during peri-adolescence decouples the prefrontal cortex: a multimodal MRI study. Am J Transl Res. 2021 PMID: 34377346
196. Iriah SC, Borges C, Shalev U, Cai X, Madularu D, Kulkarni PP, **Ferris CF**. The utility of maraviroc, an antiretroviral agent used to treat HIV, as treatment for opioid abuse? Data from MRI and behavioural testing in rats. J Psychiatry Neurosci. 2021 PMID: 34625487
197. Ortiz RJ, Wagler AE, Yee JR, Kulkarni PP, Cai X, **Ferris CF**, Cushing BS. Functional connectivity differences between two culturally distinct prairie vole populations: insights into the prosocial network. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 PMID: 34839018

198. Cai X, Harding IC, Sadaka AH, Colarusso B, Kulkarni P, Ebong E, Qiao J, O'Hare NR, **Ferris CF**. Mild repetitive head impacts alter perivascular flow in the midbrain dopaminergic system in awake rats. Brain Commun. 2021.PMID: 34806002.
199. Leaston J, Kulkarni P, Gharagouzloo C, Qiao J, Bens N, **Ferris CF**. Do We Swallow the Waste From Our Brain? Front Neurosci. 2021 PMID: 34887724
200. Leaston J, Qiao J, Harding IC, Kulkarni P, Gharagouzloo C, Ebong E, **Ferris CF** Quantitative Imaging of Blood-Brain Barrier Permeability Following Repetitive Mild Head Impacts. Front Neurol. 2021 PMID: 34659094
201. **Ferris CF** and Kulkarni P In vivo Neuropathology: Detecting the Neurotoxicity of Candidate Drugs during Early Drug Discovery, J Experimental Neurology (Commentary) 2021 2 (4) 177-178.
202. **Ferris CF**. Applications in Awake Animal Magnetic Resonance Imaging, Front Neurosci. 2022 PMID: 35450017.
203. Padmakumar S, Kulkarni P, **Ferris CF**, Bleier BS, Amiji MM. Traumatic brain injury and the development of parkinsonism: Understanding pathophysiology, animal models and therapeutic targets Biomed Pharmacother. 2022 PMID: 35290887
205. Otto LD, Russart KLG, Kulkarni P, McTigue DM, **Ferris CF**, Pyter LM. Paclitaxel Chemotherapy Elicits Widespread Brain Anisotropy Changes in a Comprehensive Mouse Model of Breast Cancer Survivorship: Evidence From In Vivo Diffusion Weighted Imaging Front Oncol. 2022 PMID: 35402248
206. Coleman JR, Madularu D, Ortiz RJ, Athanassiou M, Knudsen A, Alkisar I, Cai X, Kulkarni PP, Cushing BS, **Ferris CF**. Changes in brain structure and function following chronic exposure to inhaled vaporised cannabis during periadolescence in female and male mice: A multimodal MRI study Addict Biol. 2022 PMID: 35470553
207. Kawazoe K, McGlynn R, Felix W, Sevilla R, Liao S, Kulkarni P, **Ferris CF**. Dose-dependent effects of esketamine on brain activity in awake mice: A BOLD phMRI study. Pharmacol Res Perspect. 2022 PMID: 36504448
208. Ortiz RJ, Wagler AE, Yee JR, Kulkarni PP, Cai X, **Ferris CF**, Cushing BS. Functional Connectivity Differences Between Two Culturally Distinct Prairie Vole Populations: Insights Into the Prosocial Network. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022 PMID: 34839018
209. Ash H, Chang A, Ortiz RJ, Kulkarni P, Rauch B, Colman R, **Ferris CF**, Ziegler TE. Structural and functional variations in the prefrontal cortex are associated with learning in pre-adolescent common marmosets (*Callithrix jacchus*). Behav Brain Res. 2022 PMID: 35595058
210. Milbocker KA, LeBlanc GL, Brengel EK, Hekmatyar KS, Kulkarni P, **Ferris CF**, Klintsova AY. Reduced and delayed myelination and volume of corpus callosum in an animal model of Fetal Alcohol Spectrum Disorders partially benefit from voluntary exercise. Science Reports 2022 PMID:

35739222

211. Ortiz R, Yee JR, Kulkarni PP, Solomon NG, Keane B, Cai X, **Ferris CF**, Cushing BS. Differences in Diffusion-Weighted Imaging and Resting-State Functional Connectivity Between Two Culturally Distinct Populations of Prairie Vole. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022 PMID: 33239258.
- 212 Kenkel WM, Ortiz RJ, Yee JR, Perkeybile AM, Kulkarni P, Carter CS, Cushing BS, **Ferris CF**. Neuroanatomical and functional consequences of oxytocin treatment at birth in prairie voles Psychoneuroendocrinology. 2023.PMID: 36709631
- 213 Taylor A, Nweke A, Vincent V, Oke M, Kulkarni P, **Ferris CF**. Chronic exposure to inhaled vaporized cannabis high in Δ^9 -THC alters brain structure in adult female mice. Front Neurosci. 2023.PMID: 36950131
- 214 Danoff JS, Page EA, Perkeybile AM, Kenkel WM, Yee JR, **Ferris CF**, Carter CS, Connelly JJ. Transcriptional diversity of the oxytocin receptor in prairie voles: mechanistic implications for behavioral neuroscience and maternal physiology. Front Genet. 2023.PMID: 37705612
- 215 Stokes C, White EF, Todd S, Bens N, Kulkarni P, **Ferris CF**. Whole CNS 3D Cryo-Fluorescence Tomography Shows CSF Clearance along Nasal Lymphatics, Spinal Nerves, and Lumbar/Sacral Lymph Nodes. J Imaging. 2023.PMID: 36826964
- 216 Sadaka AH, Canuel J, Febo M, Johnson CT, Bradshaw HB, Ortiz R, Ciumo F, Kulkarni P, Gitcho MA, **Ferris CF**. Effects of inhaled cannabis high in Δ^9 -THC or CBD on the aging brain: A translational MRI and behavioral study. Front Aging Neurosci. 2023.PMID: 36819730
- 217 Sathe PK, Ramdasi GR, Giammatteo K, Beauzile H, Wang S, Zhang H, Kulkarni P, Booth RG, **Ferris CF**. Effects of (-)-MBP, a novel 5-HT_{2C} agonist and 5-HT_{2A/2B} antagonist/inverse agonist on brain activity: A phMRI study on awake mice. Pharmacol Res Perspect. 2023.PMID: 37837184
- 218 Brems BM, Sullivan EE, Connolly JG, Zhang J, Chang A, Ortiz R, Cantwell L, Kulkarni P, Thakur GA, **Ferris CF**. Dose-dependent effects of GAT107, a novel allosteric agonist-positive allosteric modulator (ago-PAM) for the $\alpha 7$ nicotinic cholinergic receptor: a BOLD phMRI and connectivity study on awake rats. Front Neurosci. 2023.PMID: 37424993.
219. DSouza AA, Kulkarni P, **Ferris CF**, Amiji MM, Bleier BS Mild repetitive TBI reduces brain-derived neurotrophic factor (BDNF) in the substantia nigra and hippocampus: A preclinical model for testing BDNF-targeted therapeutics. Exp Neurol. 2024 PMID: 38244886.
220. Harris-Blum L, Smith Z, Ortiz RJ, Athreya D, Chang A, Kulkarni PP, **Ferris CF** Developmental changes in brain structure and function following exposure to oral LSD during adolescence. Sci Rep. 2024 PMID: 39128924.
221. Bens N, Kulkarni P, **Ferris CF** Changes in cerebral vascular reactivity following mild repetitive head injury in awake rats: modeling the human experience. Exp Brain Res. 2024 PMID: 39162729.
220. Ghaw A, Chunduri A, Chang A, Ortiz RJ, Kozłowska M, Kulkarni PP, **Ferris CF** Dose-dependent

LSD effects on cortical/thalamic and cerebellar activity: brain oxygen level-dependent fMRI study in awake rats. Brain Commun. 2024 PMID: 38863575.

221. Colarusso B, Ortiz R, Yeboah J, Chang A, Gupta M, Kulkarni P, **Ferris CF**. APOE4 rat model of Alzheimer's disease: sex differences, genetic risk and diet. BMC Neurosci. 2024 PMID: 39506641.
222. Balaji S, Woodward TJ, Richter E, Chang A, Otiz R, Kulkarni PP, Balaji K, Bradshaw HB, **Ferris CF**. Palmitoylethanolamide causes dose-dependent changes in brain function and the lipidome. Front Neurosci. 2024 PMID: 39664446.
223. Iriah SC, Rodriguez N, Febo M, Morrisette M, Strandwitz P, Kulkarni P, **Ferris CF**. The microbiome's influence on the neurobiology of opioid addiction and brain connectivity. Brain Res Bull. 2024. PMID: 39645048.
224. Ognibene JM, Desai RI, Kulkarni PP, **Ferris CF**. Chronic exposure to inhaled vaporized cannabis high in Δ^9 -THC suppresses Adderall-induced brain activity. Front Pharmacol. 2024 PMID: 39494344.
225. Hightower R, Brengel E, Prom S, Kulkarni P, Ferris CF. Testing the Efficacy of Minocycline Treatment in an Awake, Female Rat Model of Repetitive Mild Head Injury. J Exp Neurol. 2024;5(3):145-161. doi.org/10.33696/Neurol.5.097

REVIEWS, BOOKS, INVITED PAPERS, PUBLIC TELEVISION, PUBLIC RADIO

1. Leeman, S.E., Aronin, N. and **Ferris, C.F.** Substance P and Neurotensin, In: Recent Progress for Hormone Research (O. Greep, ed.), Academic Press, Inc., New York 38:93-132, 1982.
2. **Ferris, C.F.** Neurotensin In: Handbook of Physiology: Section on the Gastrointestinal System. Neuroendocrinology of the Gut. (G.M. Makhlof, ed.) pp 559-585, 1989.
3. **Ferris, C.F.** Vasopressin and social behaviors in the golden hamster, In: Proceedings of the Third International Vasopressin Conference, Ed. S. Jard and R Jamison, Colloque INSERM/John Libbey Eurotext Ltd. Vol. 208, pp 185-193 1991.
4. Albers, H.E., **C.F. Ferris**, E.G. Stopa, R.T. Zoeller, Neurochemistry of circadian timing. In: Suprachiasmatic Nucleus: The Mind's Clock Ed D Klein, R. Moore, and S Reppert, Oxford University Press, 1991.
5. **Ferris, C.F.** Role of vasopressin in aggressive and dominant/subordinate behaviors In: Oxytocin in Maternal, Sexual and Social Behavior, Eds C.A. Pederson, J. Caldwell, Annals of the New York Academy of Sciences 652:212-226, 1992.
6. **Ferris, C.F.** National Public Radio, Talk of the Nation Science Friday, Biology of Violence November 6th, 1995.
7. **Ferris, C.F.**, Rage of Innocence The Sciences (March/April) 1996.
8. Understanding Aggressive Behavior in Children; Eds. **C.F. Ferris** and T. Grisso Annals of the New York Academy of Sciences, New York, N.Y. vol 794, 1996.

9. **Ferris, C.F.** and G.J. DeVries, Ethological models for examining the neurobiology of aggressive and affiliative behaviors. In: Handbook of Antisocial Behavior; Eds. D.Stoff, J. Breiling and J.D. Maser; John Wiley and Sons, Inc. New York Chapter 24, pgs 255-268 (1997).
10. **Ferris, C.F.** Discovery Channel, Canada, Killer Instinct, Part I: Aggression, Noah Erenberg, producer; aired September 1, 1997.
11. **Ferris, C.F.** Crackdown on Crime: Taking Back Our Neighborhoods. Ivanhoe Broadcast News, aired May 1998.
12. **Ferris, C.F.** Gray Matters: The Teenage Brain The Dana Alliance for Brain Initiatives, aired November 1998.
13. **Ferris, C.F.**, D.P. Olson, J.A. King, Functional magnetic resonance imaging in animals: applications in psychiatric research, In: Contemporary Strategies in Psychiatric Neuroimaging Research, eds. D. Dougherty, S. Rauch, J. Rosenbaum, American Psychiatric Press, Inc. pgs 367-382, 2001.
14. **Ferris, C.F.** Discovery Channel, Canada, Rage of Innocence, Noah Erenberg, producer; aired March, 2000.
15. **Ferris, C.F.** The Associated Press, by Matt Crenson: Gray Matter, Not Raging Hormones Rules Adolescence. January 2001.
16. Roots of Mental Illness in Children, Eds. J.A. King, **C.F. Ferris**, I.I. Lederhendler, Annals of the New York Academy of Sciences, 2004.
17. **Ferris, C.F.** Animal studies on inappropriate aggressive behavior following stress and alcohol exposure in adolescence. In: Developmental Psychobiology of Aggression ed D.M. Stoff, E. J. Susman, Cambridge University Press pgs 69-86 2005.
18. **Ferris, C.F.**, C.T. Snowdon. Functional magnetic resonance imaging in conscious marmoset monkeys: Methods and applications in neuroscience research. In: The Laboratory Primate: Handbook of Experimental Animals, ed. S. Wolfe-Coate, Academic Press, Elsevier Science pgs 353-359 2005
19. **Ferris, C.F.** Neuroplasticity and Aggression: Interaction Between Serotonin and Vasopressin. In: Biology of Aggression ed. Randy J. Nelson, Oxford University Press, pgs163-178, 2005.
20. **Ferris, C.F.** Vasopressin/Oxytocin and Aggression, In: Molecular Mechanisms Influencing Aggressive Behaviours, ed Jamie Goode, Novartis Foundation Symposium 268:190-200, 2005.
21. Simon, N.G. and **Ferris, C.F.** (2009) Aggression: Hormonal Basis. In: Squire LR (ed.) Encyclopedia of Neuroscience, volume 1 pp 149-158. Oxford: Academic Press.
22. Fabio, K., C. Guillon, S. Lu, N.D. Heindel, M. Miller, **C.F. Ferris**, M.J. Brownstein, C. Garripa, M. Steiner, E. Coccaro, E. Damiano, G.A. Koppel, N.G. Simon. Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments, in: Frontiers in CNS Drug Discovery eds A. Rahman, M.I.Choudhary, vol 1 pp 156-183 (2010).

23. **Ferris C.F.**, Smerkers B, Kulkarni P, Caffrey M, Afacan O, Toddes S, Stolberg T, Febo M. Functional magnetic resonance imaging in awake animals. Reviews in Neuroscience. 22:665-674, (2011).
24. **Ferris, C.F.**, Melloni, R.H., Jr., and Albers, H.E. Role of Vasopressin in Flank Marking and Aggression. In *Oxytocin, Vasopressin and Related Peptides in the Regulation of Behavior*, E. Choleris, D. Pfaff, and M. Kavaliers (eds.), Cambridge University Press. (2013)
25. **Ferris, C.F.**, M. Febo, and P Kulkarni, Small Animal Imaging as a Tool for Modeling CNS Disorders: Strengths and Weaknesses, In *Translational NeuroImagin,g* R.A. McArthur (ed) Elsevier Press (2013)
26. **Ferris, C.F.** and Jeffery Tenney, Functional Magnetic Resonance Imaging in Epilepsy: Methods and Applications Using Awake Animals In: *Neuronal Networks in Brain Function, CNS Disorders, and Therapeutics*. C. Faingold and H. Blumenfeld (eds), Elsevier Press, (2013).
27. **Ferris, C.F.** Using Awake Animal Imaging to Understand Neural Circuits of Emotion: Studies Raging from Maternal Care to Aggression. In: Research and Perspectives in Neuroscience, Ipsen Foundation, *New Frontiers in Social Neuroscience*. J Decety and Y Christen (eds), Springer Press, (2014)
28. **Ferris, C.F.** Using Awake Animal Imaging to Finger Print Drugs for CNS Liability: Risk for Suicide? In: *Suicide Phenomenology and Neurobiology*, Cannon KE and Hudzik TJ (eds), Chapter 16, pgs 261-272 Springer Press (2014)
29. **Ferris CF** and Kulkarni P In vivo Neuropathology: Detecting the Neurotoxicity of Candidate Drugs during Early Drug Discovery, J Experimental Neurology (Commentary) 2021 2 (4) 177-178.